After Indivior (INDV) reduced FY24 guidance due to the removal of automatic Medicaid coverage renewals for Sublocade, Jefferies caught up with both Neurocrine (NBIX) and Alkermes’ (ALKS) management teams and notes that neither is seeing a Sublocade-like impact regarding Medicaid claims going into Q2. The firm maintains a Buy rating and $175 price target on Neurocrine shares and a Buy rating and $50 price target on Alkermes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine announces FDA accepted two NDAs
- Neurocrine presented CAHtalyst Phase 3 studies at ENDO 2024
- Neurocrine announces CAHtalyst Pediatric Phase 3 study met primary endpoint
- Neurocrine announces CAHtalyst Phase 3 study met primary endpoint
- Neurocrine Biosciences Announces CEO Retirement and Succession